26% of US adults take 4+ prescription drugs daily: This cohort is the most likely to struggle with affording their meds. Pharma marketers need to raise awareness of cost-saving offerings to boost medication adherence among patients.
23andMe files for bankruptcy: A sale could give the acquiring company access to 15 million people’s genetic data. 23andMe’s downfall is a reminder of the risks when tech companies collect sensitive health data and struggle to sufficiently protect it.
Consumers blame Insurers, pharma for the state of US healthcare: Both industries continue to face serious trust issues with consumers that marketing alone won’t fix.
Self-pay patients can now get discounted Wegovy at retail pharmacies: It’s a smart play on the part of Novo Nordisk to make its GLP-1 available at pharmacies where most consumers still get their prescriptions. Will rival Eli Lilly follow suit?
Peloton owns half of all at-home fitness market sales, according to a February Earnest Analytics survey.
Pharmacy deserts increase across the US, mostly in rural areas: More pharmacy closures are expected, which means medication access for many patients will worsen before it improves.
Weight loss drug ads are prevalent on digital media: But these ads are often misleading, and younger consumers are particularly at risk of falling for deceptive weight loss drug offerings.
Nurses are still in short supply: There are efforts to improve nurse satisfaction. But more nurses are quitting than being hired, and patients’ trust in quality of care is at risk.
Google’s AI Overviews for health will include people’s suggestions: It’s a recognition that consumers want to hear from their peers in addition to verified sources of medical information.
GLP-1 weight loss drugs aren’t worth their high price tag: A new study gives commercial and government insurers another reason to deny GLP-1 drug coverage.
UnitedHealth Group’s Optum Rx changes pharmacy reimbursement model: It will pay pharmacies more to dispense brand-name drugs. But that’s not enough to thwart off the Trump administration’s heat on pharmacy benefit managers like Optum.
Use of digital health tools varies across generations: Here’s what marketers need to know about how different age groups engage with telehealth, connected health devices, and health data-sharing activities.
Pharma industry hopes for drug-price delay dashed again: As the Trump administration pushes ahead with another round of IRA prescription drug-price negotiations, a delay seems unlikely.
Novartis, NFL strike corporate sponsorship deal: The partnership likely won’t focus on promoting Novartis products but is still a great opportunity for the drugmaker to build brand awareness.
Lawmakers investigate telehealth tie-ups with pharma: Despite more scrutiny over potential conflicts of interest, we expect even more Big Pharma D2C launches this year.
Noom expands into hormone replacement therapy: Companies must tread carefully as they enter a new prescription drug segment that comes with medical risks.
Consumers believe they were misled about COVID-19: Their trust in public health leadership will likely only worsen as federal agencies purge personnel and messaging on medical treatments and protective measures gets muddier.
US wearables forecast 2025: Health and wellness features are driving consumer adoption of wearables. AI-powered capabilities could be next. But doctors aren’t as enthusiastic about relying on health data in their practice—yet.
Consumers trust social health influencers’ medical advice: The influencer opportunity is one that can’t be ignored by healthcare and pharma brands.
Trump health leaders lean into supplements: As public health agency leaders promote vitamin and mineral supplements, brands and marketers need to maintain trusted science and education messages.